Treatment of Primary FSGS with Nephrotic Syndrome in Adults

This protocol covers first-line immunosuppressive management for adults diagnosed with primary focal segmental glomerulosclerosis (FSGS) who present with nephrotic syndrome and have no relative contraindications or intolerance to glucocorticoids.

Clinical Scenario

The target population is adults with primary FSGS presenting with nephrotic syndrome, who are appropriate candidates for glucocorticoid-based immunosuppression — that is, without relative contraindications or intolerance to this class of therapy.

Primary FSGS Nephrotic syndrome Glucocorticoid-eligible First-line

Treatment Approach

Guidelines recommend high-dose oral glucocorticoid-based immunosuppression as the first-line therapy in this population. Treatment is continued with the goal of achieving remission, with specific duration criteria, response benchmarks, and tapering guidance detailed in the full protocol.

Dosing, duration rules, response thresholds, and subsequent tapering are available in the full regimen below.

Treatment Goals

The primary targets are reduction of proteinuria and achievement of complete remission. Some degree of proteinuria reduction is generally observed before 16 weeks of treatment, often within the first several weeks of initiating therapy.

Instant Access to Structured Evidence-Based Regimens

References

We recommend that high-dose oral glucocorticoids be used as the first-line immunosuppressive treatment for primary FSGS (1D).
In adults with relative contraindications or intolerance to glucocorticoids, alternative immunosuppression with CNIs should be considered as the initial therapy in patients with primary FSGS (Figure 54).
Initial high-dose glucocorticoids should be continued until complete remission is achieved, or as tolerated by patients up to a maximum of 16 weeks, whichever is earlier.
Generally demonstrate some degree of proteinuria reduction before 16 weeks, often within 4–8 weeks of initiating treatment.

View source ↗